H-Index & Metrics Top Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine H-index 236 Citations 267,801 3,498 World Ranking 18 National Ranking 14

Research.com Recognitions

Awards & Achievements

2012 - Fellow of the American Association for the Advancement of Science (AAAS)

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Leukemia

Hagop M. Kantarjian spends much of his time researching Internal medicine, Leukemia, Gastroenterology, Myeloid leukemia and Surgery. Hagop M. Kantarjian has researched Internal medicine in several fields, including Immunology and Oncology. His Leukemia research is multidisciplinary, incorporating elements of Myeloid, Myelodysplastic syndromes and Pharmacology.

Within one scientific family, he focuses on topics pertaining to Chemotherapy under Gastroenterology, and may sometimes address concerns connected to Acute promyelocytic leukemia. His studies deal with areas such as Adverse effect and Fms-Like Tyrosine Kinase 3 as well as Myeloid leukemia. Hagop M. Kantarjian works mostly in the field of Chronic myelogenous leukemia, limiting it down to topics relating to Philadelphia chromosome and, in certain cases, Acute lymphocytic leukemia, as a part of the same area of interest.

His most cited work include:

  • Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia (4424 citations)
  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (2888 citations)
  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2837 citations)

What are the main themes of his work throughout his whole career to date?

Hagop M. Kantarjian mainly investigates Internal medicine, Oncology, Myeloid leukemia, Gastroenterology and Leukemia. His work carried out in the field of Internal medicine brings together such families of science as Surgery and Immunology. His Oncology research is multidisciplinary, incorporating perspectives in Transplantation, Cancer, Myelodysplastic syndromes and Decitabine.

He combines subjects such as Tyrosine kinase and Bone marrow with his study of Myeloid leukemia. His studies in Gastroenterology integrate themes in fields like Refractory, Phases of clinical research, Adverse effect, Neutropenia and Myelofibrosis. His biological study spans a wide range of topics, including Myeloid and Pharmacology.

He most often published in these fields:

  • Internal medicine (70.44%)
  • Oncology (32.15%)
  • Myeloid leukemia (27.24%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (70.44%)
  • Oncology (32.15%)
  • Myeloid leukemia (27.24%)

In recent papers he was focusing on the following fields of study:

Hagop M. Kantarjian focuses on Internal medicine, Oncology, Myeloid leukemia, Cancer research and In patient. His work on Internal medicine is being expanded to include thematically relevant topics such as Gastroenterology. The Oncology study combines topics in areas such as Chemotherapy, Blinatumomab, Lymphoblastic Leukemia, Decitabine and Transplantation.

His work deals with themes such as Refractory, Myeloid, Azacitidine, Venetoclax and Bone marrow, which intersect with Myeloid leukemia. Hagop M. Kantarjian interconnects Tyrosine kinase, Mutant and Stem cell in the investigation of issues within Cancer research. The various areas that Hagop M. Kantarjian examines in his Leukemia study include Cancer and Clinical trial.

Between 2017 and 2021, his most popular works were:

  • Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. (571 citations)
  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML (526 citations)
  • Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study (291 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

Internal medicine, Oncology, Myeloid leukemia, Leukemia and Gastroenterology are his primary areas of study. His Oncology research integrates issues from Hematopoietic stem cell transplantation, Transplantation, Phases of clinical research, Philadelphia chromosome and Blinatumomab. His Philadelphia chromosome research includes elements of Nilotinib, Ponatinib and Dasatinib.

His research in Myeloid leukemia focuses on subjects like Azacitidine, which are connected to Febrile neutropenia and Myelodysplastic syndromes. His Leukemia research incorporates themes from Survival rate, Cancer and Clinical trial. His Gastroenterology study combines topics from a wide range of disciplines, such as Hypomethylating agent and Bone marrow.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Top Publications

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian J. Druker;Moshe Talpaz;Debra J. Resta;Bin Peng.
The New England Journal of Medicine (2001)

6767 Citations

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)

4164 Citations

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)

3961 Citations

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

Timothy J. Ley;Christopher Miller;Li Ding;Benjamin J. Raphael.
The New England Journal of Medicine (2013)

3697 Citations

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Brian J. Druker;Charles L. Sawyers;Hagop M Kantarjian;Debra J. Resta.
The New England Journal of Medicine (2001)

3592 Citations

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot.
The New England Journal of Medicine (2002)

2532 Citations

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz.
Blood (2012)

2252 Citations

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus.
Blood (2013)

2068 Citations

A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover.
The New England Journal of Medicine (2003)

2009 Citations

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Moshe Talpaz;Neil P. Shah;Hagop M Kantarjian;Nicholas Donato.
The New England Journal of Medicine (2006)

1987 Citations

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us

Top Scientists Citing Hagop M. Kantarjian

Ayalew Tefferi

Ayalew Tefferi

Mayo Clinic

Publications: 330

Andreas Hochhaus

Andreas Hochhaus

Friedrich Schiller University Jena

Publications: 301

Giovanni Martinelli

Giovanni Martinelli

University of Bologna

Publications: 297

Pierre Fenaux

Pierre Fenaux

Université Paris Cité

Publications: 282

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 278

John C. Byrd

John C. Byrd

University of Cincinnati

Publications: 274

Brian J. Druker

Brian J. Druker

Oregon Health & Science University

Publications: 255

Peter Valent

Peter Valent

Medical University of Vienna

Publications: 247

Elihu H. Estey

Elihu H. Estey

Fred Hutchinson Cancer Research Center

Publications: 245

Richard Stone

Richard Stone

Harvard University

Publications: 243

Michele Baccarani

Michele Baccarani

University of Bologna

Publications: 239

Ross L. Levine

Ross L. Levine

Memorial Sloan Kettering Cancer Center

Publications: 237

Ruben A. Mesa

Ruben A. Mesa

The University of Texas Health Science Center at San Antonio

Publications: 230

Michael W. Deininger

Michael W. Deininger

Huntsman Cancer Institute

Publications: 225

Giuseppe Saglio

Giuseppe Saglio

University of Turin

Publications: 219

Something went wrong. Please try again later.